keverprazan hydrochloride + amoxicillin

Keverprazan hydrochloride + amoxicillin is a fixed-dose combination therapy under investigation for the eradication of Helicobacter pylori (H. pylori) infection, particularly as a rescue or first-line treatment. Keverprazan hydrochloride is a novel potassium-competitive acid blocker (P-CAB) that provides rapid and sustained gastric acid suppression by inhibiting the H+-K+-ATPase enzyme at the potassium binding site in gastric parietal cells. This mechanism is independent of CYP2C19 polymorphism and offers advantages over traditional proton pump inhibitors (PPIs), such as faster onset and more stable acid inhibition[1][6][9]. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins[5]. The dual regimen aims to optimize H. pylori eradication rates while minimizing adverse effects and improving patient compliance compared to quadruple therapies[1][2][3].

Other names

keverprazan-amoxicillin dual therapykeverprazan hydrochloride combined with amoxicillin